| Name | Larsucosterol trimethylamine |
| Description | Larsucosterol trimethylamine (DUR-928 trimethylamine) is a potent liver X receptor (LXR) antagonist that modulates endogenous epigenetics, reduces lipid accumulation in hepatocytes, attenuates lipopolysaccharide (LPS) and TNFα-induced inflammatory responses in macrophages, and alleviates LPS- and acetaminophen (ATMP)-induced multi-organ damage. |
| In vitro | In a model of HG-induced MASLD in humanhepatocytes, Larsucosterol exhibits a specific inhibition of DNMTs. This results in the conversion of 5mCpG to CpG in the promoter regions of 1,074 genes within hepatocytes, leading to the upregulation of genes associated with key sig-naling pathways such as MAPK-ERK, calcium-AMPK, andtype II diabetes mellitus pathways. [1] |
| In vivo | In a mouse hepatectomy model, larsucosterol upregulates the expression of genes associated with cell replication, including Wt1 (Wilms’ tumor 1),PCNA (proliferating cell nuclear antigen), cMyc (myelocyto-matosis oncogene), cyclin A, FoxM1b (Forkhead Box M1b),and CDC25b (M-phase inducer phosphatase 2), whereas con-currently downregulating the expression of cell cycle arrestgene Chek2 (checkpoint kinase 2) and the apoptotic geneApaf1 (apoptotic peptidase activating factor 1). [1] |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 20 mg/mL (39.27 mM), Sonication is recommended.
|
| Keywords | LXR | LiverXReceptor | Liver X Receptor |
| Inhibitors Related | SR9243 | GW6340 | T0901317 | GSK3987 | RGX-104 | SR9238 | GSK2033 | BE1218 | (20S)-Protopanaxatriol | GW3965 hydrochloride | LXR-623 | Rovazolac |
United States
